Orzeyful / Oveporexton for Narcolepsy Type 1

As of August 2026, MARA’s assessment finds Orzeyful / Oveporexton’s reimbursement risk concentrated in comparator selection, with evidence quality and robustness a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs safety and adverse effects: what harms arrive alongside the benefit, which payers set against the gains before funding a treatment. The strength recorded in evidence quality and robustness carries weight because that domain asks how solid the underlying evidence is on its own terms — trial design, size and endpoints — before any question of price is reached.

Neurology

This rating sits within MARA’s Neurology coverage, alongside 61 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

Phase 3 trials showed significant improvements in wakefulness and symptom relief, with high confidence in short-term efficacy. However, no head-to-head data versus active comparators are available.

Does the economic case hold at the expected price? — Cost effectiveness

No peer-reviewed cost-effectiveness study is available. ICER review indicates potential cost-effectiveness at a certain price range, but no actual pricing or long-term data is available.

Is there quality-of-life evidence payers weigh? — Quality of life

Trials reported significant gains on validated QoL tools like SF-36 and EQ-5D-5L. However, no direct utility values were reported, and long-term durability of QoL benefits is untested.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Trials reported mostly mild-to-moderate AEs with no serious treatment-related adverse events. Long-term safety is uncertain due to lack of data beyond months.

Was the drug compared against what payers expect? — Comparator Selection

Trials used placebo as the comparator, which limits direct applicability to practice. No active comparator trials were conducted.

Is the population defined the way payers need it? — Patient Population and Subgroups

Trial participants were representative of the NT1 population, but no subgroup analyses were reported, and data on pediatric and very elderly patients is lacking.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Oveporexton is poised as a first-line therapy for NT1, potentially simplifying management. No special infrastructure or training is required.

Are the wider system costs understood? — Resource Use and Cost Implications

No published analyses on direct medical costs or cost savings. Economic impacts are speculative at this stage.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

Evidence comes from rigorous Phase 3 RCTs with robust statistical significance. However, trials lacked active comparators and were relatively short.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

Key uncertainties include long-term outcomes and real-world adherence. Financial and long-term projections are low confidence.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Public record

The entries below are official decisions and assessments concerning this drug and indication, listed with their dates as a matter of record. The assessment on this page reflects the evidence available as of its date.

8 June 2026 — United States (ICER), evidence report: final evidence report: adequate net health benefit found versus available treatments. official record

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.